阿德福韦酯对HBV相关性肝癌发生预测指标的影响

摘要

Objective To observe the effects of adefovir dipivoxil on the forecast indexes of HBV-related hepatocellular carcinoma. Methods Total of 58 CHB patients were treated with adefovir dipivoxil (Hepsera®, 10 mg, qd, oral empty). The serum ALT, albumin, total serum bilirubin, HBV DNA and AFP were detected. Results After treatment with adefovir dipivoxil for 96 weeks, the detection value of total serum bilirubin, ALT, HBV DNA and a-fetoprotein (AFP) decreased significantly (P = 0.000). The HCC predicting scores dropped from (19.46 ± 1.48) to (6.07±1.05), the difference was significant (t = 56.20, P = 0.000). Conclusions The present study demonstrated that long-term treatment with adefovir dipivoxil for CHB leads to a sustained virological and biochemical effect. The HCC predicting scores of CHB patients dropped after treatment with adefovir dipivoxil.%目的：探讨阿德福韦酯治疗乙型肝炎过程中对乙型肝炎病毒（HBV）相关性肝癌发生风险预测指标的影响。方法58例慢性乙型肝炎患者均给予阿德福韦酯片（贺维力10 mg/次，空腹口服，1次/d）治疗。测定血清ALT、白蛋白、总胆红素、HBV DNA及甲胎蛋白含量。结果经阿德福韦酯治疗96周后，患者血清白蛋白、血清总胆红素、谷丙转氨酶、HBV DNA载量和AFP均得到明显改善，差异均具有显著统计学意义（P =0.000）；HCC预测评分平均值由治疗前（19.46±1.48）分降低至（6.07±1.05）分，差异具有显著统计学意义（t =56.20，P =0.000）。结论阿德福韦酯的规范合理治疗能够将HBV载量控制在较低的水平，改善ALT、白蛋白、总胆红素和AFP等HBV相关性肝癌发生风险的预测指标。